Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease

Brain

Volumn 125, Issue 11, 2002, Pages 2431-2445

  Harding, Antony J ^a,b   Stimson, Emily ^a   Henderson, Jasmine M ^a   Halliday, Glenda M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

Amygdala; Lewy body; Neuronal loss; Parkinson's disease; synuclein

Indexed keywords

ALPHA SYNUCLEIN; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; HYPNOTIC SEDATIVE AGENT; LEVODOPA; NEUROLEPTIC AGENT;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEPRESSION; DISEASE DURATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEWY BODY; MALE; MENTAL DISEASE; NERVE CELL DEGENERATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; VISUAL HALLUCINATION;

EID: 0036844873     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awf251     Document Type: Article

References (84)

1. Adolphs R, Tranel D, Damasio H, Damasio A. Impaired recognition of emotion in facial expressions following bilateral damage to the human amygdala. Nature 1994; 372: 669-72.
2. Aggleton JP. The functional effects of amygdala lesions in humans: A comparison with findings from monkeys. In: Aggleton JP, editor. The Amygdala: Neurobiological Aspects of Emotion, Memory, and Mental Dysfunction. New York: Wiley-Liss; 1992. p. 485-503.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th Ed. Washington (DC): American Psychiatric Association; 1994.
4. Anderson AK, Phelps EA. Intact recognition of vocal expressions of fear following bilateral lesions of human amygdala. Neuroreport 1998; 9: 3607-13.
5. Anderton BH. Changes in the ageing brain in health and disease. [Review]. Philos Trans R Soc Lond B Biol Sci 1997; 352: 1781-92.
6. Bancaud J, Brunet-Bourgin F, Chauvel P, Halgren E. Anatomical origin of deja vu and vivid 'memories' in human temporal lobe epilepsy. Brain 1994; 117: 71-90.
7. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. [Review]. Acta Neuropathol (Berl) 1991; 82: 239-59.
8. Braak H, Braak E, Yilmazer D, de Vos R, Jansen E, Bohl J, et al. Amygdala pathology in Parkinson's disease. Acta Neuropathol (Berl) 1994; 88: 493-500.
9. Braak H, Braak E, Yilmazer D, Schultz C, de Vos RAI, Jansen EN. Nigral and extranigral pathology in Parkinson's disease. [Review]. J Neural Transm 1995; Suppl 46: 15-31.
10. Broks P, Young AW, Maratos EJ, Coffey PJ, Calder AJ, Isaac CL et al. Face processing impairments after encephalitis: Amygdala damage and recognition of fear. Neuropsychologia 1998; 36: 59-70.
11. Cahill L, Babinsky R, Markowitsch HJ, McGaugh JL. The amygdala and emotional memory. Nature 1995; 377: 295-6.
12. Churchyard A, Lees AJ. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology 1997; 49: 1570-6.
13. Cordato NJ, Halliday GM, Harding AJ, Hely MA, Morris JG. Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. Ann Neurol 2000; 47: 718-28.
14. Darvesh S, Grantham DL, Hopkins DA. Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. J Comp Neurol 1998; 393: 374-90.
15. Davidson RJ, Pizzagalli D, Nitschke JB, Putnam K. Depression: Perspectives from affective neuroscience. [Review]. Annu Rev Psychol 2002; 53: 545-74.
16. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 1999; 58: 376-388.
17. de la Monte SM, Wells SE, Hedley-Whyte E, Growdon JH. Neuropathological distinction between Parkinson's dementia and Parkinson's plus Alzheimer's disease. Ann Neurol 1989; 26: 309-20.
18. de Olmos JS. Amygdala. In: Paxinos G, editor. The Human Nervous System. San Diego: Academic Press; 1990. p. 583-710.
19. Dickson DW. Pick's disease: A modern approach. [Review]. Brain Pathol 1998; 8: 339-54.
20. Dickson DW. Tau and synuclein and their role in neuropathology. [Review]. Brain Pathol 1999; 9: 657-61.
21. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: A general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988; 38: 1237-44.
22. Double KL, Halliday GM, McRitchie DA, Reid WG, Hely MA, Morris JG. Regional brain atrophy in idiopathic Parkinson's disease and diffuse Lewy body disease. Dementia 1996; 7: 304-13.
23. Drevets WC. Neuroimaging and neuropathological studies of depression: Implications for the cognitive-emotional features of mood disorders. [Review]. Curr Opin Neurobiol 2001; 11: 240-9.
24. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 1991; 114: 2283-301.
25. Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors. Brain 2000; 123: 733-45.
26. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson's disease. Arch Neurol 1999; 56: 33-9.
27. Gloor P. The amygdaloid system. In: Gloor P. The temporal lobe and limbic system. New York: Oxford University Press; 1997. p. 591-721.
28. Gorno-Tempini ML, Pradelli S, Serafini M, Pagnoni G, Baraldi P, Porro C, et al. Explicit and incidental facial expression processing: An fMRI study. Neuroimage 2001; 14: 465-73.
29. Gray TS. Functional and anatomical relationships among the amygdala, basal forebrain, ventral striatum, and cortex. An integrative discussion. [Review]. Ann NY Acad Sci 1999; 877: 439-44.
30. Hague K, Lento P, Morgello S, Caro S, Kaufmann H. The distribution of Lewy bodies in pure autonomic failure: autopsy findings and review of the literature. [Review]. Acta Neuropathol (Berl) 1997; 94: 192-6.
31. Halliday GM, McRitchie DA, Cartwright H, Pamphlett R, Hely MA, Morris JGL. Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. J Clin Neurosci 1996; 3: 52-60.
32. Hamilton RL. Lewy bodies in Alzheimer's disease: A neuropathological review of 145 cases using α-synuclein immunohistochemistry. Brain Pathol 2000; 10: 378-84.
33. Harding AJ, Halliday GM. Simplified neuropathological diagnosis of dementia with Lewy bodies. Neuropathol Appl Neurobiol 1998; 24: 195-201.
34. Harding, AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (Berl) 2001; 102: 355-63.
35. Harding AJ, Halliday GM, Cullen K. Practical considerations for the use of the optical disector in estimating neuronal number. J Neurosci Methods 1994; 51: 83-9.
36. Harding AJ, Kril JJ, Halliday GM. Practical measures to simplify the Braak tangle staging method for routine pathological screening. Acta Neuropathol (Berl) 2000; 99: 199-208.
37. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002a; 125: 391-403.
38. Harding AJ, Lakay B, Halliday GM. Selective hippocampal neuron loss in dementia with Lewy bodies. Ann Neurol 2002b; 51: 125-8.
39. Hawkes CH, Shephard BC. Selective anosmia in Parkinson's disease? Lancet 1993; 341: 435-436.
40. Henderson JM, Carpenter K, Cartwright H, Halliday GM. Degeneration of the centre-median-parafascicular complex in Parkinson's disease. Ann Neurol 2000; 47: 345-52.
41. Henderson JM, Gai WP, Hely MA, Reid WG, Walker GL, Halliday GM. Parkinson's disease with late Pick's dementia. Mov Disord 2001; 16: 311-9.
42. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology 1967; 17: 427-42.
43. Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM-Y, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000; 54: 1916-21.
44. Imamura T, Ishii K, Hirono N, Hashimoto M, Tanimukai S, Kazuai H, et al. Visual hallucinations and regional cerebral metabolism in dementia with Lewy bodies (DLB). Neuroreport 1999; 10: 1903-7.
45. Iseki E, Odawara T, Li F, Kosaka K, Nishimura T, Akiyama H, et al. Age-related ubiquitin-positive granular structures in non-demented subjects and neurodegenerative disorders. J Neurol Sci 1996; 142: 25-9.
46. Iseki E, Kato M, Marui W, Uéda K, Kosaka K. A neuropathological study of the disturbance of the nigro-amygdaloid connections in brains from patients with dementia with Lewy bodies. J Neurol Sci 2001; 185: 129-34.
47. Jacobs DH, Shuren J, Bowers D, Heilman KM. Emotional facial imagery, perception, and expression in Parkinson's disease. Neurology 1995; 45: 1696-702.
48. Kanazawa I. How do neurons die in neurodegenerative diseases? Trends Mol Med 2001; 7: 339-344.
49. Kim H, Gearing M, Mirra SS. Ubiquitin-positive CA2/3 neurites in hippocampus coexist with cortical Lewy bodies. Neurology 1995; 45: 1768-70.
50. Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 1998; 153: 1365-70.
51. Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ. Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol 1999; 45: 353-7.
52. Lovestone S, McLoughlin DM. Protein aggregates and dementia: Is there a common toxicity? [Review]. J Neurol Neurosurg Psychiatry 2002; 72: 152-61.
53. Maccioni RB, Munoz JP, Barbeito L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. [Review]. Arch Med Res 2001; 32: 367-81.
54. Mann DM. Anosmia in dementia is associated with Lewy bodies rather than Alzheimer's pathology. J Neurol Neurosurg Psychiatry 2001; 70: 720-1.
55. Mattila PM, Rinne JO, Helenius H, Dickson DW, Röyttä M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol (Berl) 2000; 100: 285-90.
56. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. [Review]. Neurology 1996; 47: 1113-24.
57. McShane RH, Nagy Z, Esiri MM, King E, Joachim C, Sullivan N, et al. Anosmia in dementia is associated with Lewy bodies rather than Alzheimer's pathology. J Neurol Neurosurg Psychiatry 2001; 70: 739-43.
58. Mesholam RI, Moberg PJ, Mahr RN, Doty RL. Olfaction in neurodegenerative diseases. Arch Neurol 1998; 55: 84-90.
59. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-86.
60. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989; 39: 1159-65.
61. Morris JS, DeGelder B, Weiskrantz L, Dolan RJ. Differential extrageniculostriate and amygdala responses to presentation of emotional faces in a cortically blind field. Brain 2001; 124: 1241-52.
62. National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. [Review]. Neurobiol Aging 1997; 18 (4 Suppl): S1-2.
63. Pearce RK, Hawkes CH, Daniel SE. The anterior olfactory nucleus in Parkinson's disease. Mov Disord 1995; 10: 283-7.
64. Petrovich GD, Canteras NS, Swanson LW. Combinatorial amygdalar inputs to hippocampal domains and hypothalamic behavior systems. [Review]. Brain Res Brain Res Rev 2001; 1: 247-89.
65. Poewe W, Luginger E. Depression in Parkinson's disease: impediments to recognition and treatment options. [Review]. Neurology 1999; 52 (7 Suppl 3): S2-6.
66. Potogas C, Dellatolas G, Ziegler M, Leveteau J, Bathien N, MacLeod P, et al. Clinical assessment of olfactory dysfunction in Parkinson's disease. Mov Disord 1998; 13: 394-9.
67. Rezaie P, Cairns NJ, Chadwick A, Lantos PL. Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease. Neurosci Lett 1996; 212: 111-4.
68. Rosenkranz JA, Grace AA. Cellular mechanisms of infralimbic and prelimbic prefrontal cortical inhibition and dopaminergic modulation of basolateral amygdala neurons in vivo. J Neurosci 2002; 22: 324-37.
69. Santhouse AM, Howard RJ, Ffytche DH. Visual hallucinatory syndromes and the anatomy of the visual brain. Brain 2000; 123: 2055-64.
70. Schmidt ML, Martin JA, Lee VM, Trojanowski JQ. Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders. Acta Neuropathol (Berl) 1996; 91: 475-81.
71. Shekhar A, Sajdyk TS, Keim SR, Yoder KK, Sanders SK. Role of the basolateral amygdala in panic disorder. Ann NY Acad Sci 1999; 877: 747-50.
72. Sims KS, Williams RS. The human amygdaloid complex: A cytologic and histochemical atlas using Nissl, myelin, acetylcholinesterase and nicotinamide adenine dinucleotide phosphate diaphorase staining. Neuroscience 1990; 36: 449-72.
73. Smith MC, Smith MK, Ellgring H. Spontaneous and posed facial expression in Parkinson's disease. J Int Neuropsychol Soc 1996; 2: 383-91.
74. Swanson LW. Cerebral hemisphere regulation of motivated behavior. [Review]. Brain Res 2000; 886: 113-64.
75. Swanson LW, Petrovich GD. What is the amygdala? [Review]. Trends Neurosci 1998; 21: 323-331.
76. Tebartz van Elst L, Ebert D, Trimble MR. Hippocampus and amygdala pathology in depression [letter]. Am J Psychiatry 2001; 158: 652-3.
77. Tebartz van Elst L, Baeumer D, Lemieux L, Woermann FG, Koepp M, Krishnamoorthy S, et al. Amygdala pathology in psychosis of epilepsy. A magnetic resonance imaging study in patients with temporal lobe epilepsy. Brain 2002; 125: 140-9.
78. Terry RD. Do neuronal inclusions kill the cell? [Review]. J Neural Transm 2000; Suppl 59: 91-3.
79. Tissingh G, Berendse HW, Bergmans P, DeWaard R, Drukarch B, Stoof JC, et al. Loss of olfaction in de novo and treated Parkinson's disease: Possible implications for early diagnosis. Mov Disord 2001; 16: 41-6.
80. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. [Review]. Eur Neurol 1997; 38 Suppl 2: 2-7.
81. Yamazaki M, Arai Y, Baba M, Iwatsubo T, Mori O, Katayama Y, et al. α-Synuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam. J Neuropathol Exp Neurol 2000; 59: 585-91.
82. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 1983; 17: 37-49.
83. Yilmazer-Hanke DM, Wolf HK, Schramm J, Elger CE, Wiestler OD, Blümcke I. Subregional pathology of the amygdala complex and entorhinal region in surgical specimens from patients with pharmacoresistant temporal lobe epilepsy. J Neuropathol Exp Neurol 2000; 59: 907-20.
84. Young AW, Aggleton JP, Hellawell DJ, Johnson M, Broks P, Hanley JR. Face processing impairments after amygdalotomy. Brain 1995; 118: 15-24.